跳至主要内容
临床试验/NCT02099149
NCT02099149撤回不适用

Establishing a Sero-correlate of Protection Against Invasive Group B Streptococcus Disease in Newborns and Young Infants Aged Less Than 90 Days.

Novartis1 个研究点 分布在 1 个国家开始时间: 2014年5月最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
发起方
Novartis
试验地点
1
主要终点
Early onset Group B Streptococcus Disease due to serotypes Ia or III

研究概览

简要总结

Compare anticapsular antibody levels against Group B Streptococcus at delivery in mothers and their infants who develop disease versus those who do not. Use this comparison to establish antibody levels associated with reductions in risk of GBS disease in infants aged less than 90 days.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Pregnant women attending participating community/hospital antenatal clinics and/or delivering at participating delivery centers.
  • Subjects aged ≥18 years.
  • Able to understand and comply with planned study procedures.
  • Provides written informed consent.

排除标准

  • Refuses to consent to study participation.

结局指标

主要结局

Early onset Group B Streptococcus Disease due to serotypes Ia or III

时间窗: 0-6 days

Risk of early onset Group B Streptococcus disease (due to serotypes Ia or III) with respect to maternal or newborn anticapsular antibody levels at delivery

次要结局

  • Late onset Group B Streptococcus Disease due to serotype III(7-90 days)

研究者

发起方
Novartis
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验